Orasis Press Releases

Orasis Pharmaceuticals Doubles Down on Eye Care Professionals, Not Telehealth, as QLOSI® Refills Reach 49.1%

Orasis Pharmaceuticals — Mon, 20 Jul 2026 20:39:03 GMT

Two new offerings are now available, a First Fill Free program through pharmacy partner BlinkRx, and an in-office dispensing option, giving eye care professionals more ways to help patients start and stay on Qlosi.

Orasis Pharmaceuticals Announces Australia Submission of a New Drug Application for BESKA for the Treatment of Presbyopia

Orasis Pharmaceuticals — Wed, 15 Jul 2026 03:00:00 GMT

Submission of New Drug Application (NDA) in Australia by Aspen Pharmacare Australia (Aspen Australia) marks the first ex-U.S. regulatory submission (known as QLOSI® in the U.S.)

New Data Demonstrate Qlosi™ Is Pupil Selective With Ciliary Muscle Movement No Different Than A Balanced Salt Solution (BSS) Control | Orasis Pharmaceuticals

Orasis Pharmaceuticals — Tue, 27 Jan 2026 03:20:06 GMT

In an imaging study from the Bascom Palmer Eye Institute, Qlosi’s low-concentration formulation with 0.4% pilocarpine significantly reduced pupil diameter while demonstrating ciliary muscle movement the same as BSS control1

Orasis Pharmaceuticals Expands Access To Qlosi™ With New Starter Packs For Eye Care Professionals, Bolstering Commercial Rollout

Orasis Pharmaceuticals — Thu, 13 Nov 2025 12:45:45 GMT

Since its U.S. launch in April 2025, Qlosi has seen strong market adoption and refill rates

Orasis Pharmaceuticals Announces Novel Corrective Eyedrop for Presbyopia, Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, Now Available to Prescribe in the U.S.

Orasis Pharmaceuticals — Mon, 07 Apr 2025 04:00:18 GMT

Qlosi’s proprietary EyeQ Formulation™ maximizes efficacy while minimizing side effects and offers patients flexible dosing – one or two drops a day – for up to eight hours of clear near vision

Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% in Korea

Orasis Pharmaceuticals — Wed, 16 Oct 2024 04:30:33 GMT

Exclusive Agreement Includes $18 Million in Milestone Payments to Orasis, Together with a Double-Digit Royalty on Sales in the Korean Market

Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%

Orasis Pharmaceuticals — Tue, 08 Oct 2024 05:01:28 GMT

$68 Million Series D Financing Co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc.

Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia

Orasis Pharmaceuticals — Tue, 17 Oct 2023 21:01:22 GMT

QLOSI™ is a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials
Affecting more than 128 million people in the U.S., presbyopia is the loss of ability to focus on near objects as a result of the natural aging process

Ponte Vedra, FL, October 18, 2023 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on reshaping vision possibilities, today announced that the U.S. Food and Drug Administration (FDA) has approved QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. QLOSI is expected to be commercially available in the U.S. in the first half of 2024.

FDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia

Orasis Pharmaceuticals — Mon, 20 Feb 2023 22:00:27 GMT

– Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023

Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

Orasis Pharmaceuticals — Tue, 03 Jan 2023 05:49:28 GMT

– Presbyopia is the loss of ability to focus on near objects as a result of the natural aging